Suraksha Diagnostic Reports Strong FY26 Revenue Growth

Suraksha Diagnostic Limited announced its financial results for the fiscal year ending March 31, 2026 (FY26), reporting a total revenue of ₹313.60 crore. This represents a significant 22.5% increase compared to ₹255.90 crore in FY25. The company also saw its EBITDA rise to ₹98.60 crore from ₹85.10 crore in the prior year, while Profit After Tax (PAT) saw a modest increase to ₹31.40 crore from ₹31.00 crore.

Strong Q4 Performance Boosts Full Year Results

In the fourth quarter of FY26 (Q4 FY26), Suraksha Diagnostic's revenue grew by 24.7% to ₹82.20 crore, up from ₹65.90 crore in Q4 FY25. EBITDA for the quarter increased to ₹25.20 crore, an improvement from ₹20.00 crore year-on-year. PAT in Q4 FY26 reached ₹6.20 crore, up from ₹2.20 crore in the same period last year.

Expansion Drives Growth, Margin Concerns Emerge

The company's impressive revenue increase stems from its strategic expansion, transitioning from a state-level operator to a broader regional player across eastern and northeastern India. However, this aggressive growth phase brings challenges. Investors are closely watching the impact of opening new centers on overall profitability and margins. Management has guided for approximately 15% revenue growth in FY27, with an aim to stabilize EBITDA margins around 33%.

Focus on New Center Ramp-Up and IT Enhancements

As of March 2026, Suraksha Diagnostic operated 68 centers. The current focus is on successfully ramping up the performance of its newly established facilities. The company plans significant capital expenditure of about ₹70 crore for FY27 to support this expansion. Additionally, IT system refinements are underway, which may temporarily affect the reporting of patient growth metrics.

Margin Pressure from New Centers

A key risk highlighted is margin contraction, with FY26 EBITDA margins falling to 31.8% from 33.8% in FY25. This dip is attributed to costs associated with new center rentals and pre-operative expenses. The ability of these new centers to mature and contribute positively to margins will be critical.

Future Outlook and Investor Watchpoints

Suraksha Diagnostic's mature centers continue to perform well, showing strong EBITDA margins between 36-37%. For FY27, investors will be monitoring the company's progress in achieving its guided 15% revenue growth and stabilizing EBITDA margins. Tracking the performance and maturation of new centers will be crucial for understanding the company's path to sustained profitability.

Key Financials at a Glance:

• FY26 Revenue: ₹313.60 crore (up 22.5% YoY)
• FY26 EBITDA: ₹98.60 crore
• FY26 PAT: ₹31.40 crore
• FY26 EBITDA Margin: 31.8% (down from 33.8% in FY25)
• FY27 Revenue Guidance: ~15% growth
• FY27 EBITDA Margin Guidance: Stabilize around 33%
• Planned FY27 Capex: ~₹70 crore